Top 10 Hot Stocks with the Highest Upside Potential

8. Oruka Therapeutics, Inc. (NASDAQ:ORKA)

6-Month Performance: 193.20%

Average Price Target Upside Potential According to Analysts: 46.80%

Oruka Therapeutics, Inc. (NASDAQ:ORKA) ranks among the top 10 hot stocks with the highest upside potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the stock.

This update comes after AbbVie announced that it is acquiring Apogee Therapeutics. AbbVie said that it has entered into a definitive agreement to acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma.

Apogee’s pipeline includes zumilokibart (APG777), a lead asset. It is a subcutaneous half-life extended monoclonal antibody that targets IL-13 and is being developed as a treatment for atopic dermatitis. The company is also developing APG273, a combination of zumilokibart and APG333, an anti-TSLP half-life extended monoclonal antibody, for the treatment of asthma.

H.C. Wainwright noted that both Apogee and Oruka Therapeutics, Inc. (NASDAQ:ORKA) were created by privately-held Paragon Therapeutics and share several similarities. The firm said both companies focus on developing treatments for inflammatory and immune-related diseases, with a particular emphasis on inflammatory skin conditions.

Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a biopharmaceutical company focused on developing novel biologics for the treatment of chronic skin diseases.